Cargando…

Immune checkpoint analysis in ear cancer

BACKGROUND: Among cutaneous squamous cell carcinomas, the ear (ecSCC) is one of the most common sites. Loco regional lymph node metastasis is found in six to eleven percent of cases, corresponding to increased metastasis compared to other sites. The aim of this study was to test the markers PD-L1, P...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, M., Polgart, E., Hallermann, C., Schulze, H. J., Hölzle, F., Wermker, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626725/
https://www.ncbi.nlm.nih.gov/pubmed/37932810
http://dx.doi.org/10.1186/s13005-023-00395-w
_version_ 1785131396958781440
author Klein, M.
Polgart, E.
Hallermann, C.
Schulze, H. J.
Hölzle, F.
Wermker, K.
author_facet Klein, M.
Polgart, E.
Hallermann, C.
Schulze, H. J.
Hölzle, F.
Wermker, K.
author_sort Klein, M.
collection PubMed
description BACKGROUND: Among cutaneous squamous cell carcinomas, the ear (ecSCC) is one of the most common sites. Loco regional lymph node metastasis is found in six to eleven percent of cases, corresponding to increased metastasis compared to other sites. The aim of this study was to test the markers PD-L1, PD-1, CD4, CD8, and FoxP3 for suitability as prognostic predictive markers. METHODS: Sixty-four patients with ecSCC were included in this study. The expression of immunohistochemical markers (PD-L1, PD-1, CD4, CD8, FOXP3) was correlated with retrospective clinic pathological parameters (lymph node metastasis, distant metastasis, lymph node metastasis during follow-up, disease progression, disease-specific death). RESULTS: There was a correlation between increased disease specific death and a weak Foxp3 (p = 0.003) or reduced CD8 (p = 0.04). A PD-L1 expression > 1% was found in 39.1% of patients. CONCLUSION: The investigated markers (CD4, CD8, FoxP3, PD-1, PD-L1) seem overall rather inappropriate for prognostic evaluation in ecSCC. Only the correlation of disease specific death with CD8 or FoxP3 seems to be worth testing in larger collectives.
format Online
Article
Text
id pubmed-10626725
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106267252023-11-07 Immune checkpoint analysis in ear cancer Klein, M. Polgart, E. Hallermann, C. Schulze, H. J. Hölzle, F. Wermker, K. Head Face Med Research BACKGROUND: Among cutaneous squamous cell carcinomas, the ear (ecSCC) is one of the most common sites. Loco regional lymph node metastasis is found in six to eleven percent of cases, corresponding to increased metastasis compared to other sites. The aim of this study was to test the markers PD-L1, PD-1, CD4, CD8, and FoxP3 for suitability as prognostic predictive markers. METHODS: Sixty-four patients with ecSCC were included in this study. The expression of immunohistochemical markers (PD-L1, PD-1, CD4, CD8, FOXP3) was correlated with retrospective clinic pathological parameters (lymph node metastasis, distant metastasis, lymph node metastasis during follow-up, disease progression, disease-specific death). RESULTS: There was a correlation between increased disease specific death and a weak Foxp3 (p = 0.003) or reduced CD8 (p = 0.04). A PD-L1 expression > 1% was found in 39.1% of patients. CONCLUSION: The investigated markers (CD4, CD8, FoxP3, PD-1, PD-L1) seem overall rather inappropriate for prognostic evaluation in ecSCC. Only the correlation of disease specific death with CD8 or FoxP3 seems to be worth testing in larger collectives. BioMed Central 2023-11-06 /pmc/articles/PMC10626725/ /pubmed/37932810 http://dx.doi.org/10.1186/s13005-023-00395-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Klein, M.
Polgart, E.
Hallermann, C.
Schulze, H. J.
Hölzle, F.
Wermker, K.
Immune checkpoint analysis in ear cancer
title Immune checkpoint analysis in ear cancer
title_full Immune checkpoint analysis in ear cancer
title_fullStr Immune checkpoint analysis in ear cancer
title_full_unstemmed Immune checkpoint analysis in ear cancer
title_short Immune checkpoint analysis in ear cancer
title_sort immune checkpoint analysis in ear cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626725/
https://www.ncbi.nlm.nih.gov/pubmed/37932810
http://dx.doi.org/10.1186/s13005-023-00395-w
work_keys_str_mv AT kleinm immunecheckpointanalysisinearcancer
AT polgarte immunecheckpointanalysisinearcancer
AT hallermannc immunecheckpointanalysisinearcancer
AT schulzehj immunecheckpointanalysisinearcancer
AT holzlef immunecheckpointanalysisinearcancer
AT wermkerk immunecheckpointanalysisinearcancer